ALT1 * Stock Overview
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Altimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$123.00 |
| 52 Week High | US$246.00 |
| 52 Week Low | US$44.00 |
| Beta | 0.20 |
| 1 Month Change | -42.25% |
| 3 Month Change | -21.41% |
| 1 Year Change | n/a |
| 3 Year Change | -54.95% |
| 5 Year Change | n/a |
| Change since IPO | -71.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALT1 * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | -2.8% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ALT1 * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how ALT1 * performed against the MX Market.
Price Volatility
| ALT1 * volatility | |
|---|---|
| ALT1 * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ALT1 *'s share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ALT1 *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
| ALT1 * fundamental statistics | |
|---|---|
| Market cap | Mex$8.80b |
| Earnings (TTM) | -Mex$1.56b |
| Revenue (TTM) | Mex$6.91m |
1,275x
P/S Ratio-5.6x
P/E RatioIs ALT1 * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALT1 * income statement (TTM) | |
|---|---|
| Revenue | US$410.00k |
| Cost of Revenue | US$70.04m |
| Gross Profit | -US$69.63m |
| Other Expenses | US$23.14m |
| Earnings | -US$92.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | -16,982.20% |
| Net Profit Margin | -22,626.10% |
| Debt/Equity Ratio | 0% |
How did ALT1 * perform over the long term?
See historical performance and comparison